Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - CAPRICOR THERAPEUTICS, INC. | tm205377d1_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - CAPRICOR THERAPEUTICS, INC. | tm205377d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - CAPRICOR THERAPEUTICS, INC. | tm205377d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - CAPRICOR THERAPEUTICS, INC. | tm205377d1_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - CAPRICOR THERAPEUTICS, INC. | tm205377d1_ex21-1.htm |
| EX-4.1 - EXHIBIT 4.1 - CAPRICOR THERAPEUTICS, INC. | tm205377d1_ex4-1.htm |
| 10-K - FORM 10-K - CAPRICOR THERAPEUTICS, INC. | tm205377d1_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of Capricor Therapeutics, Inc. and Subsidiary
Los Angeles, California
We consent to the incorporation by reference in the Registration Statements of Capricor Therapeutics, Inc. on Form S-8 (File Nos. 333-152283, 333-175727, 333-194317, and 333-215510), Form S-3 (File Nos. 333-161339, 333-165167, 333- 207149, 333-212017, 333-219188, and 333-227955), and Form S-1 (File No. 333-235358) of our report dated March 26, 2020, relating to the consolidated financial statements, appearing in this Annual Report on Form 10-K.
/s/ Rose, Snyder & Jacobs LLP
Rose, Snyder & Jacobs LLP
Encino, California
March 26, 2020